About: Teriflunomide

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Teriflunomide Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B5A46-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5A47-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B5A48-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R: A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006 Mar 28;66(6):894-900. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16567708 # Tallantyre E, Evangelou N, Constantinescu CS: Spotlight on teriflunomide. Int MS J. 2008 Jun;15(2):62-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18782502 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	The median half-life is 18 to 19 days. (en)
http://linked.open...ugbank/indication	Used in the treatment of relapsing forms of multiple sclerosis (MS). (en)
sameAs	Teriflunomide
Title	Teriflunomide (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB08880/identifier/chebi/68540 http://linked.opendata.cz/resource/drugbank/drug/DB08880/identifier/drugbank/DB08880 http://linked.opendata.cz/resource/drugbank/drug/DB08880/identifier/kegg-drug/D10172 http://linked.opendata.cz/resource/drugbank/drug/DB08880/identifier/national-drug-code-directory/58468-0210-1 http://linked.opendata.cz/resource/drugbank/drug/DB08880/identifier/wikipedia/Teriflunomide
http://linked.open...mechanismOfAction	The exact mechanism by which teriflunomide acts in MS is not known. What is known is that teriflunomide prevents pyrimidine synthesis by inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase, and this may be involved in its immunomodulatory effect in MS. (en)
http://linked.open...outeOfElimination	Teriflunomide is eliminated unchanged and mainly through bile. Specifically 37.5% is eliminated in the feces and 22.6% in urine. (en)
http://linked.open.../drugbank/synonym	Aubagio (en) HMR 1726 (en) HMR1726 (en) Teriflunomida (en) Teriflunomidum (en) a 77-1726 (en) a 771726 (en) (Z)-2-Cyano-alpha,alpha,alpha-trifluoro-3-hydroxy-P-crotonotoluidide (en)
http://linked.open...drugbank/toxicity	Teriflunomide is contraindicated in pregnant women or women of childbearing age due to the risk of teratogenicity. Teriflunomide is also contraindicated in severe hepatic impairment due to reports of hepatotoxicity, hepatic failure, and death. (en)
http://linked.open...umeOfDistribution	After a single intravenous dose, the volume of distribution is 11 L. (en)
http://linked.open...k/foodInteraction	Food does not affect teriflunomide pharmacokinetics, so take with or without food. (en)
http://linked.open...nk/proteinBinding	Teriflunomide is extensively plasma protein bound(>99%). (en)
http://linked.open...ynthesisReference	Keshav Deo, Samir Patel, Snehal Dhol, Sunil Sanghani, Vishal Ray, " PROCESS FOR PREPARING TERIFLUNOMIDE." U.S. Patent US20110092727, issued April 21, 2011. (en)
foaf:page	http://www.drugs.com/mtm/teriflunomide.html http://www.rxlist.com/aubagio-drug.htm
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B5A49-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Teriflunomide
http://linked.open...ugbank/absorption	After oral administration of teriflunomide, maximum plasma concentrations are reached, on average, in 1-4 hours. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	163451-81-8 (en)
http://linked.open...rugbank/clearance	After a single IV dose, teriflunomide has a total body clearance of 30.5 mL/h. (en)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 26 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software